News & Events – Page 6 – www.brainwork.md

1st November 2017

ECTRIMS-ACTRIMS: A conversation with Prof. Till Sprenger

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 1st November 2017 13th July 2018

I had the chance to meet up with Professor Sprenger at ECTRIMS-ACTRIMS in Paris last week. We discussed the TEMSO study, which has been evaluating the…

Lutz Achtnichts, MD
0
0

1st November 2017

ECTRIMS-ACTRIMS: A conversation with Dr Patricia Mulero

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 1st November 2017 13th July 2018

At ECTRIMS-ACTRIMS in Paris, France, I had the chance to sit down with Dr Patricia Mulero to discuss FLOODLIGHT: a prospective pilot study that has…

Lutz Achtnichts, MD
0
0

31st October 2017

ECTRIMS-ACTRIMS: A conversation with Dr Tanuja Chitnis

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 31st October 2017 13th July 2018

Children and adolescents living with MS face physical and cognitive disability that can severely limit their ability to perform daily activities, such as attending school.…

Lutz Achtnichts, MD
1
0

30th October 2017

ECTRIMS-ACTRIMS: Updates to safety of ocrelizumab in pregnancy still “ongoing” after new analysis

https://www.brainwork.md/content/uploads/2017/10/Brainwork-Pregnancy.jpg 898 599 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 30th October 2017 13th July 2018

An update on pregnancy outcomes following ocrelizumab (OCR) treatment in patients with multiple sclerosis (MS) and other autoimmune diseases was delivered at this year’s joint…

Peter Stevenson, PhD
0
0

30th October 2017

ECTRIMS-ACTRIMS: Teriflunomide for multiple sclerosis: is it safe in pregnancy?

https://www.brainwork.md/content/uploads/2017/10/MPR426-Brainwork-illustrations-articles-V00-02-20171027_baby.png 898 506 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 30th October 2017 13th July 2018

Friday’s programme at the ECTRIMS-ACTRIMS meeting in Paris played host to an exploration of pregnancy outcomes in multiple sclerosis (MS) patients treated with teriflunomide – …

Peter Stevenson, PhD
0
0

30th October 2017

ECTRIMS-ACTRIMS: Phase III data EXPAND on siponimod for secondary progressive multiple sclerosis

https://www.brainwork.md/content/uploads/2017/10/MPR426-Brainwork-illustrations-articles-V00-02-20171027_brain.png 898 506 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 30th October 2017 13th July 2018

Data presented at the recent 7th joint ECTRIMS-ACTRIMS meeting in Paris delved deeper into the efficacy of siponimod in the treatment of secondary progressive MS…

Peter Stevenson, PhD
0
0

27th October 2017

Welcome to Brainwork

https://www.brainwork.md/content/uploads/2017/10/MPR426-Brainwork-illustrations-articles-V00-02-20171027_neurons.png 899 506 Prof. Dr. Krassen Nedeltchev Prof. Dr. Krassen Nedeltchev https://secure.gravatar.com/avatar/aaadc696c1b66fe476051e7e4012d01a?s=96&d=mm&r=g 27th October 2017 27th October 2017

Dear colleagues, Thank you for subscribing to BRAINWORK! Your participation has made our eLearning initiative stronger and more wide-ranging! What is Brainwork? Brainwork is a…

Prof. Dr. Krassen Nedeltchev
3
7

27th October 2017

ECTRIMS-ACTRIMS: OBOE study explores biomarkers of neurodegeneration and inflammation in multiple sclerosis

https://www.brainwork.md/content/uploads/2017/10/welcome-to-brainwork-ectrims-2017.jpg 1920 1080 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 27th October 2017 13th July 2018

The development and characterisation of biomarkers in multiple sclerosis (MS) could be a crucial step in understanding disease pathways, as well as the therapeutic mechanisms…

Peter Stevenson, PhD
0
0

Brainwork-DiabeticDrugMayBenefitHigh-RiskStrokePatients

25th October 2017

Diabetes drug may benefit high-risk stroke patients

https://www.brainwork.md/content/uploads/2017/10/Brainwork-DiabeticDrugMayBenefitHigh-RiskStrokePatients.jpg 4064 2710 Camilla Norrmén, PhD Camilla Norrmén, PhD https://secure.gravatar.com/avatar/c5fc8d4c102d9ee8db3f93d7f9c6ecd2?s=96&d=mm&r=g 25th October 2017 13th July 2018

A study showed last year that the insulin-sensitizing drug pioglitazone reduces the risk for stroke in patients with recent ischemic strokes. A new secondary analysis…

Camilla Norrmén, PhD
0
0

24th October 2017

NAVIGATE ESUS: Rivaroxaban vs aspirin study terminated due to comparable efficacy

https://www.brainwork.md/content/uploads/2017/10/Brainwork-NavigateESUS.jpg 2992 2000 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th October 2017 13th July 2018

Early discontinuation has been announced for the Phase III NAVIGATE ESUS study – led by Bayer AG and its development partner Janssen Research & Development,…

Peter Stevenson, PhD
0
0

ECTRIMS-ACTRIMS: A conversation with Prof. Till Sprenger

ECTRIMS-ACTRIMS: A conversation with Dr Patricia Mulero

ECTRIMS-ACTRIMS: A conversation with Dr Tanuja Chitnis

ECTRIMS-ACTRIMS: Updates to safety of ocrelizumab in pregnancy still “ongoing” after new analysis

ECTRIMS-ACTRIMS: Teriflunomide for multiple sclerosis: is it safe in pregnancy?

ECTRIMS-ACTRIMS: Phase III data EXPAND on siponimod for secondary progressive multiple sclerosis

Welcome to Brainwork

ECTRIMS-ACTRIMS: OBOE study explores biomarkers of neurodegeneration and inflammation in multiple sclerosis

​Diabetes drug may benefit high-risk stroke patients

​NAVIGATE ESUS: Rivaroxaban vs aspirin study terminated due to comparable efficacy

Diabetes drug may benefit high-risk stroke patients

NAVIGATE ESUS: Rivaroxaban vs aspirin study terminated due to comparable efficacy